Methylene blue improves the hepatopulmonary syndrome. (2000)

Peer-Reviewed Study · Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C · November 7, 2000

Schenk P et al., 2000-11-07: Open uncontrolled trial in seven Austrian patients with severe hepatopulmonary syndrome: intravenous methylene blue 3 mg/kg raised PaO2 from 58 to 74 mmHg by five hours.

Intravenous methylene blue improved hypoxemia and hyperdynamic circulation in patients with liver cirrhosis and severe hepatopulmonary syndrome.

Schenk P et al., 2000-11-07: Open uncontrolled trial in seven Austrian patients with severe hepatopulmonary syndrome: intravenous methylene blue 3 mg/kg raised PaO2 from 58 to 74 mmHg by five hours. C10. Open, uncontrolled trial, N=7, medical ICU, University Hospital Vienna, Austria. Dose: 3 mg/kg IV over 15 minutes. Outcomes: PaO2 58 to 74 mmHg at 5 h (P=0.006); alveolar-arterial gradient fell; shunt fraction 41% to 25% (P<0.001). No control group – a small uncontrolled positive study, which under the direction-only rule is SUPPORTS, not proof. Funder/conflicts not stated in this abstract. Ann Intern Med 2000;133:701-706. Study type: uncontrolled series.